Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with mild-moderate fibrosis, with or without glucose abnormalities: interim results of the EGG18 study

V Calvaruso,S Petta,D Ferraro,C La Mantia,G Reina,A Zarcone,E Assanto,V Di Marco,A Craxì

doi:10.1016/j.dld.2019.12.107

Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with mild-moderate fibrosis, with or without glucose abnormalities: interim results of the EGG18 study

V Calvaruso, S Petta + Show 7 more

https://doi.org/10.1016/j.dld.2019.12.107

Copy DOI

Journal: Digestive and Liver Disease

Publication Date: Feb 1, 2020

Affiliation: University of Palermo

#Hepatitis C Virus Infected Patients #Rate Of Sustained Viral Response + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and Aim: Antiviral treatment by Direct Acting Antivirals (DAAs) achieves the highest rate of sustained viral response (SVR) in patients with genotype 1b (G1b) Hepatitis C virus (HCV) infection. Reducing treatment duration can simplify the management and improve adherence of therapy.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Digestive and Liver Disease

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.